Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens (Q37812128)

23 August 2017

title

Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens (English)

1 reference

23 August 2017

Antu K Dey

1

1 reference

23 August 2017

Indresh K Srivastava

series ordinal

2

1 reference

23 August 2017

publication date

1 February 2011

1 reference

Expert Review of Vaccines

23 August 2017

number of pages

25

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

227-251

1 reference

Aluminium compounds for use in vaccines

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Aluminium adjuvants--in retrospect and prospect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Archaeosomes as self-adjuvanting delivery systems for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Mechanism of action of clinically approved adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

How do adjuvants work? Important considerations for new generation adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Approaching the asymptote? Evolution and revolution in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Seeking wisdom in innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The instructive role of innate immunity in the acquired immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A hepatitis B vaccine formulated with a novel adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Crystal structure of a new heat-labile enterotoxin, LT-IIb

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Maintenance of serological memory by polyclonal activation of human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Toll-like receptors in the induction of the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Therapeutic applications of CpG-containing oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Immunostimulatory DNA is a potent mucosal adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Advances in saponin-based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The induction of cell-associated and secreted IL-1 by iscoms, matrix or micelles in murine splenic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Quaternary structure of the immunostimulating complex (iscom).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Influenza virus ISCOMs: antibody response in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A comparison of commercially available adjuvants for use in research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Targeting the innate immune response with improved vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Bacterial fimbriae and their peptides activate human gingival epithelial cells through Toll-like receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Antiviral and antitumor peptides from insects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A novel, killed-virus nasal vaccinia virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Improving protein therapeutics with sustained-release formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

21 January 2018

HIV and mucosal immunity

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Development of a preventive vaccine for Ebola virus infection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Protection against vaginal SIV transmission with microencapsulated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Biologically erodable microspheres as potential oral drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Oral vaccination in man using antigens in particles: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Liposomes as carriers of antigens and adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Liposomal vaccines--targeting the delivery of antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

New technology platforms in the development of vaccines for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The structure and function of the hemagglutinin membrane glycoprotein of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Adjuvant and antigen delivery properties of virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Influenza virosomes as an efficient system for adjuvanted vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Virus-like particles: passport to immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The virosome concept for influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The stabilization of proteins by osmolytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Recent advances in our understanding of protein conformational stability from a pharmaceutical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

The expanding vaccine development pipeline, 1995-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Survey of human-use adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Skin immunization made possible by cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Action of Saponin on Biological Cell Membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

Liposomes as immunological adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.142

21 January 2018

Identifiers

DOI

10.1586/ERV.10.142

1 reference

23 August 2017

1 reference